Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
1 ФГБОУ ВО «Омский государственный медицинский университет» Минздрава России, Омск, Россия; 2 БУЗОО «Городской клинический перинатальный центр», Омск, Россия
Список исп. литературыСкрыть список 1. Международная классификация орофациальной боли, 1-е издание (ICOP). Адаптированная русскоязычная версия. Альманах клинической медицины. 2022; S: 3–80. DOI: 10.18786/2072-0505-2022-50-005 [Mezhdunarodnaia klassifikatsiia orofatsial'noi boli, 1-e izdanie (ICOP). Adaptirovannaia russkoiazychnaia versiia. Al'manakh klinicheskoi meditsiny. 2022; S: 3–80. DOI: 10.18786/2072-0505-2022-50-005 (in Russian).] 2. Гриневич В.Б., Губонина И.В., Дощицин В.Л. и др. Особенности ведения коморбидных пациентов в период пандемии новой коронавирусной инфекции (COVID-19). Национальный Консенсус 2020. Кардиоваскулярная терапия и профилактика. 2020; 19 (4): 2630. DOI: 10.15829/1728-8800-2020-2630 [Grinevich V.B., Gubonina I.V., Doshchitsin V.L. et al. Management of patients with comorbidity during novel coronavirus (COVID-19) pandemic. National Consensus Statement 2020. Cardiovascular Therapy and Prevention. 2020; 19 (4): 2630. DOI: 10.15829/1728-8800-2020-2630 (in Russian).] 3. Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19). Временные методические рекомендации Минздрава России. 15-я версия от 22.02.2022 г. URL: https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/059/ 392/original/%D0%92%D0%9C%D0%A0_COVID-19_V15.pdf [Profilaktika, diagnostika i lechenie novoi koronavirusnoi infektsii (COVID-19). Vremennye metodicheskie rekomendatsii Minzdrava Rossii. 15-ia versiia ot 22.02.2022 g. URL: https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/059/392/original/VMR_COVID-19_V15.pdf (in Russian).] 4. Casillas Santana MA, Arreguín Cano JA, Dib Kanán A et al. Should We Be Concerned about the Association of Diabetes Mellitus and Periodontal Disease in the Risk of Infection by SARS-CoV-2? A Systematic Review and Hypothesis. Medicina (Kaunas) 2021; 57 (5): 493. DOI: 10.3390/medicina57050493 5. Silvestre FJ, Márquez-Arrico CF. COVID-19 and Periodontitis: A Dangerous Association? Front Pharmacol 2022; 12: 789681. DOI: 10.3389/fphar.2021.789681 6. Jafer MA, Hazazi MA, Mashi MH et al. COVID-19 and Periodontitis: A Reality to Live with. J Contemp Dent Pract 2020; 21 (12): 1398–403. URL: https://pubmed.ncbi.nlm.nih.gov/33893266/#affiliation-1 7. Campisi G, Bizzoca ME, Lo Muzio L. COVID-19 and periodontitis: reflecting on a possible association. Head Face Med 2021; 17 (1): 16. DOI: 10.1186/s13005-021-00267-1 8. Kusiak A, Cichońska D, Tubaja M et al. COVID-19 manifestation in the oral cavity – a narrative literature review. Acta Otorhinolaryngol Ital 2021; 41 (5): 395–400. DOI: 10.14639/0392-100X-N1584 9. Basso L, Chacun D, Sy K et al. Periodontal Diseases and COVID-19: A Scoping Review. Eur J Dent 2021; 15 (4): 768–75. DOI: 10.1055/s-0041-1729139 10. Grigoriadis A, Räisänen IT, Pärnänen P et al. Is There a Link between COVID-19 and Periodontal Disease? A Narrative Review. Eur J Dent 2022. DOI: 10.1055/s-0041-1740223 11. Brock M, Bahammam S, Sima C. The Relationships Among Periodontitis, Pneumonia and COVID-19. Front Oral Health 2022; 2: 801815. DOI: 10.3389/froh.2021.801815 12. Qi X, Northridge ME, Hu M, Wu B. Oral health conditions and COVID-19: A systematic review and meta-analysis of the current evidence. Aging Health Res 2022; 2 (1): 100064. DOI: 10.1016/j.ahr.2022.100064 13. Biadsee A, Biadsee A, Kassem F et al. Olfactory and Oral Manifestations of COVID-19: Sex-Related Symptoms-A Potential Pathway to Early Diagnosis. Otolaryngol Head Neck Surg 2020; 163 (4): 722–8. DOI: 10.1177/0194599820934380 14. Dar-Odeh N, Bobamuratova DT, Alnazzawi A et al. Jaw-related complications in COVID-19 patients; a systematic review. Cranio 2022: 1–8. DOI: 10.1080/08869634.2022.2031438 15. Saccomanno S, Bernabei M, Scoppa F et al. Coronavirus Lockdown as a Major Life Stressor: Does It Affect TMD Symptoms? Int J Environ Res Public Health 2020; 17 (23): 8907. DOI: 10.3390/ijerph17238907 16. Manfredini D, Marini M, Pavan C et al. Psychosocial profiles of painful TMD patients. J Oral Rehabil 2009; 36 (3): 193–8. DOI: 10.1111/j.1365-2842.2008.01926.x 17. Manfredini D, Lombardo L, Siciliani G. Temporomandibular disorders and dental occlusion. A systematic review of association studies: end of an era? J Oral Rehabil 2017; 44 (11): 908–23. DOI: 10.1111/joor.12531 18. De La Torre Canales G, Câmara-Souza MB, Muñoz Lora VR et al. Prevalence of psychosocial impairment in temporomandibular disorder patients: a systematic review. J Oral Rehabil 2018; 45 (11): 881–9. DOI: 10.1111/joor.12685 19. Kindler S, Samietz S, Houshmand M et al. Depressive and anxiety symptoms as risk factors for temporomandibular joint pain: a prospective cohort study in the general population. J Pain 2012; 13 (12): 1188–97. DOI: 10.1016/j.jpain.2012.09.004 20. Boscato N, Almeida RC, Koller CD et al. Influence of anxiety on temporomandibular disorders: an epidemiological survey with elders and adults in Southern Brazil. J Oral Rehabil 2013; 40 (9): 643–9. DOI: 10.1111/joor.12076 21. Osiewicz M, Lobbezoo F, Ciapała B et al. Pain predictors in a population of temporomandibular disorders patients. J Clin Med 2020; 9 (2): 452. DOI: 10.3390/jcm9020452 22. Almeida-Leite CM, Stuginski-Barbosa J, Conti PCR. How psychosocial and economic impacts of COVID-19 pandemic can interfere on bruxism and temporomandibular disorders? J Appl Oral Sci 2020; 28: e20200263. DOI: 10.1590/1678-7757-2020-0263 23. Quadri MF, Mahnashi A, Al Almutahhir A et al. Association of awake bruxism with khat, coffee, tobacco, and stress among Jazan University Students. Int J Dent 2015; 2015: 842096. DOI: 10.1155/ 2015/842096 24. Smardz J, Martynowicz H, Wojakowska A et al. Correlation between sleep bruxism, stress, and depression-A polysomnographic study. J Clin Med 2019; 8 (9): 1344. DOI: 10.3390/jcm8091344 25. Smardz J, Martynowicz H, Michalek-Zrabkowska M et al. Sleep bruxism and occurrence of temporomandibular disorders-related pain: a polysomnographic study. Front Neurol 2019; 10: 168. DOI: 10.3389/ fneur.2019.0016 26. Polmann H, Domingos FL, Melo G et al. Association between sleep bruxism and anxiety symptoms in adults: a systematic review. J Oral Rehabil 2019; 46 (5): 482 91. DOI: 10.1111/joor.12785 27. Przystańska A, Jasielska A, Ziarko M et al. Psychosocial predictors of bruxism. Biomed Res Int 2019; 2019: 2069716. DOI: 10.1155/2019/2069716 28. Wieckiewicz M, Smardz J, Martynowicz H et al. Distribution of temporomandibular disorders among sleep bruxers and non-bruxers: a polysomnographic study. J Oral Rehabil 2020; 10.1111/joor.12955. DOI: 10.1111/joor.1295 29. Saccomanno S, Bernabei M, Scoppa F et al. Coronavirus Lockdown as a Major Life Stressor: Does It Affect TMD Symptoms? Int J Environ Res Public Health 2020; 17 (23): 8907. DOI: 10.3390/ijerph17238907 30. Machoň V, Levorová J, Beňo M, Foltán R. The Manifestations of Covid-19 Infection. Manifestations in Patients with Temporomandibular Joint Disorders. Prague Med Rep 2022; 123 (2): 95–100. DOI: 10.14712/23362936.2022.10 31. DE Caxias FP, Athayde FRF, Januzzi MS et al. Impact event and orofacial pain amid the COVID-19 pandemic in Brazil: a cross-sectional epidemiological study. J Appl Oral Sci 2021; 29: e20210122. DOI: 10.1590/1678-7757-2021-0122 32. Badrah M, Riad A, Kassem I et al. Craniofacial pain in COVID-19 patients with diabetes mellitus: Clinical and laboratory description of 21 cases. J Med Virol 2021; 93 (5): 2616–9. DOI: 10.1002/jmv.26866 33. Asquini G, Bianchi AE, Borromeo G et al. The impact of COVID-19-related distress on general health, oral behaviour, psychosocial features, disability and pain intensity in a cohort of Italian patients with temporomandibular disorders. PLoS One 2021; 16 (2): e0245999. DOI: 10.1371/journal.pone.0245999 34. Saki M, Shadmanpour M, Najafi HZ. Are individuals with orofacial pain more prone to psychological distress during the COVID-19 pandemic? Dent Med Probl 2021; 58 (1): 17–25. DOI: 10.17219/dmp/ 131683 35. Emodi-Perlman A, Eli I. One year into the COVID-19 pandemic – temporomandibular disorders and bruxism: What we have learned and what we can do to improve our manner of treatment. Dent Med Probl 2021; 58 (2): 215–8. DOI: 10.17219/dmp/132896 36. Colonna A, Guarda-Nardini L, Ferrari M, Manfredini D. COVID-19 pandemic and the psyche, bruxism, temporomandibular disorders triangle. Cranio 2021; Oct 15: 1–6. DOI: 10.1080/08869634. 2021.1989768 37. Padre A, Mourão LC. Correlation of Covid-19 With Stomatognathic System With Homeopathic Proposal for Adjunct Treatment to Increase Oral and General Health. Altern Ther Health Med 2020; 26 (S2): 112–6. https://pubmed.ncbi.nlm.nih.gov/33245703/ 38. Emodi-Perlman A, Eli I, Smardz J et al. Temporomandibular Disorders and Bruxism Outbreak as a Possible Factor of Orofacial Pain Worsening during the COVID-19 Pandemic-Concomitant Research in Two Countries. J Clin Med 2020; 9 (10): 3250. DOI: 10.3390/jcm9103250 39. Peixoto KO, Resende CMBM, Almeida EO et al. Association of sleep quality and psychological aspects with reports of bruxism and TMD in Brazilian dentists during the COVID-19 pandemic. J Appl Oral Sci 2021; 29: e20201089. DOI: 10.1590/1678-7757-2020-1089 40. Zubair AS, McAlpine LS, Gardin T et al. Neuropathogenesis and Neurologic Manifestations of the Coronaviruses in the Age of Coronavirus Disease 2019: A Review. JAMA Neurol 2020; 77 (8): 1018–27. DOI: 10.1001/jamaneurol.2020.2065 41. Sampaio Rocha-Filho PA, Voss L. Persistent Headache and Persistent Anosmia Associated With COVID-19. Headache 2020; 60 (8): 1797–9. DOI: 10.1111/head.13941 42. Tolebeyan AS, Zhang N, Cooper V, Kuruvilla DE. Headache in Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection: A Narrative Review. Headache 2020; 60 (10): 2131–38. DOI: 10.1111/head.13980 43. Medeiros KS, Macêdo LTA, Souza WF et al. Guillain-Barré syndrome associated with SARS-CoV-2 infection: a scoping review. Rev Assoc Med Bras (1992). 2021; 67 (2): 318–34. DOI: 10.1590/1806-9282.67.2.20200716 44. Brandini DA, Takamiya AS, Thakkar P et al. COVID-19 and oral diseases: Crosstalk, synergy or association? Rev Med Virol 2021; 31 (6): e2226. DOI: 10.1002/rmv.2226 45. Iranmanesh B, Khalili M, Amiri R et al. Oral manifestations of COVID-19 disease: A review article. Dermatol Ther 2021; 34 (1): e14578. DOI: 10.1111/dth.14578 46. Fakhruddin KS, Samaranayake LP, Buranawat B, Ngo H. Oro-facial mucocutaneous manifestations of Coronavirus Disease-2019 (COVID-19): A systematic review. PLoS One 2022; 17(6): e0265531. DOI: 10.1371/journal.pone.0265531 47. Gherlone EF, Polizzi E, Tetè G et al. Frequent and Persistent Salivary Gland Ectasia and Oral Disease After COVID-19. J Dent Res 2021; 100(5): 464–71. DOI: 10.1177/0022034521997112 48. Halboub E, Al-Maweri SA, Alanazi RH et al. Orofacial manifestations of COVID-19: a brief review of the published literature. Braz Oral Res 2020; 34: e124. DOI: 10.1590/1807-3107bor-2020.vol34.0124 49. Mehta R, Nagarkar NM, Ksbs KS et al. Facial Nerve Palsy in COVID-19-Associated Mucormycosis Patients: A Case Series. Cureus 2021; 13 (11): e19208. DOI: 10.7759/cureus.19208 50. Molaei H, Shojaeefar E, Nemati E et al. Iranian patients co-infected with COVID-19 and mucormycosis: the most common predisposing factor, clinical outcomes, laboratory markers and diagnosis, and drug therapies. Infect Dis (Lond) 2022: 1–14. DOI: 10.1080/23744235. 2022.2058604 51. Watanabe A, So M, Mitaka H et al. Clinical Features and Mortality of COVID-19-Associated Mucormycosis: A Systematic Review and Meta-Analysis. Mycopathologia 2022; 187 (2–3): 271–89. DOI: 10.1007/s11046-022-00627-8 52. Patel R, Jethva J, Bhagat PR et al. Rhino-orbital-cerebral mucormycosis: An epidemiological study from a tertiary care referral center in Western India. Indian J Ophthalmol 2022; 70–(4): 1371–5. DOI: 10.4103/ijo.IJO_2943_21 53. Hussain S, Baxi H, Riad A et al. COVID-19-Associated Mucormycosis (CAM): An Updated Evidence Mapping. Int J Environ Res Public Health 2021; 18 (19): 10340. DOI: 10.3390/ijerph181910340 54. Jain K, Surana A, Choudhary TS et al. Clinical and histology features as predictor of severity of mucormycosis in post-COVID-19 patients: An experience from a rural tertiary setting in Central India. SAGE Open Med 2022; 10: 20503121221074785. DOI: 10.1177/ 20503121221074785 55. Wasiq M, Gn A. Coronavirus disease-associated mucormycosis (CAM): A case control study during the outbreak in India. J Assoc Physicians India 2022; 70 (4): 11–2. URL: https://pubmed.ncbi. nlm.nih.gov/35443518/ 56. Desai EJ, Pandya A, Upadhya I et al. Epidemiology, Clinical Features and Management of Rhino Orbital Mucormycosis in Post COVID 19 Patients. Indian J Otolaryngol Head Neck Surg 2022; 74 (1): 103–7. DOI: 10.1007/s12070-021-02807-2 57. Ramphul K, Verma R, Kumar N et al. Rising concerns of Mucormycosis (Zygomycosis) among COVID-19 patients; an analysis and review based on case reports in literature. Acta Biomed 2021; 92 (4): e2021271. DOI: 10.23750/abm.v92i4.11787 58. Gupta S, Ahuja P. Risk Factors for Procurence of Mucormycosis and its Manifestations Post Covid-19: a Single Arm Retrospective Unicentric Clinical Study. Indian J Otolaryngol Head Neck Surg 2021; Sep 18: 1–8. DOI: 10.1007/s12070-021-02825-0 59. Exposto FG, Castrillon EE, Exposto CR et al. Remote physical examination for temporomandibular disorders. Pain 2022; 163 (5): 936–42. DOI: 10.1097/j.pain.0000000000002455 60. Bavarian R, Pharr CA, Handa S et al. The utility of telemedicine in orofacial pain: Guidelines for examination and a retrospective review at a hospital-based practice. J Oral Rehabil 2022. DOI: 10.1111/joor.13335 61. Lee YH. Supportive Home Remedies for Orofacial Pain during the Coronavirus Disease 2019 Pandemic: Their Value and Limitations. Int J Dent 2022: 2005935. DOI: 10.1155/2022/2005935. 62. Dar-Odeh N, Elsayed S, Babkair H et al. What the dental practitioner needs to know about pharmaco-therapeutic modalities of COVID-19 treatment: A review. J Dent Sci 2021; 16 (3): 806–16. DOI: 10.1016/j.jds.2020.11.007 63. Haastrup PF, Thompson W, Søndergaard J, Jarbøl DE. Side Effects of Long-Term Proton Pump Inhibitor Use: A Review. Basic Clin Pharmacol Toxicol 2018; 123 (2): 114–21. DOI: 10.1111/bcpt.13023 64. Трухан Д.И., Коншу Н.В. Рациональная фармакотерапия в клинике внутренних болезней сквозь призму мультиморбидности и лекарственной безопасности. Справочник поликлинического врача. 2019; 2: 10–8. URL: https://www.elibrary.ru/ item.asp?id= 44162870 [Trukhan D.I., Konshu N.V. Ratsional'naia farmakoterapiia v klinike vnutrennikh boleznei skvoz' prizmu mul'timorbidnosti i lekarstvennoi bezopasnosti. Spravochnik poliklinicheskogo vracha. 2019; 2: 10–8. URL: https://www.elibrary.ru/item.asp?id=44162870 (in Russian).] 65. Zirk-Sadowski J, Masoli JA, Delgado J et. al. Proton-Pump Inhibitors and Long-Term Risk of Community-Acquired Pneumonia in Older Adults. J Am Geriatr Soc 2018; 66 (7): 1332–8. DOI: 10.1111/jgs.15385 66. Ble A, Zirk-Sadowski J, Masoli JA. Reply to: Proton Pump Inhibitors and Long-term Risk of Community-acquired Pneumonia in Older Adults. J Am Geriatr Soc 2018; 66 (12): 2428–9. DOI: 10.1111/jgs.15637 67. Yuan J, He O, Nguyen LH et al. Regular use of proton pump inhibitors and risk of type 2 diabetes: results from three prospective cohort studies. Gut 2020 Sep 28; gutjnl-2020-322557. DOI: 10.1136/gutjnl-2020-322557 68. Schubert ML. Adverse effects of proton pump inhibitors: fact or fake news? Curr Opin Gastroenterol 2018; 34 (6): 451–7. DOI: 10.1097/ MOG.0000000000000471 69. Song TJ, Kim J. Risk of post-stroke pneumonia with proton pump inhibitors, H2 receptor antagonists and mucoprotective agents: A retrospective nationwide cohort study. PLoS One 2019; 14 (5): e0216750. DOI: 10.1371/ journal.pone.0216750 70. Targownik LE, Lix LM, Leung S, Leslie WD. Proton-pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss. Gastroenterology 2010; 138: 896–904. DOI: 10.1053/j.gastro.2009.11.014 71. Ngamruengphong S, Leontiadis GI, Radhi S et al. Proton pump inhibitors and risk of fracture: a systematic review and meta-analysis of observational studies. Am J Gastroenterol 2011; 106: 1209–18. DOI: 10.1038/ajg.2011.113 72. Makunts T, Cohen IV, Awdishu L, Abagyan R. Analysis of postmarketing safety data for proton-pump inhibitors reveals increased propensity for renal injury, electrolyte abnormalities, and nephrolithiasis. Sci Rep 2019; 9 (1): 2282. DOI: 10.1038/s41598-019-39335-7 73. Bavishi C, Dupont HL. Systematic review: The use of proton pump inhibitors and increased susceptibility to enteric infection. Aliment Pharmacol Ther 2011; 34: 1269–81. DOI: 10.1111/j.1365-2036.2011.04874.x 74. Eom CS, Jeon CY, Lim JW et al. Use of acid-suppressive drugs and risk of pneumonia: A systematic review and meta-analysis. CMAJ 2011; 183: 310–9. DOI: 10.1503/cmaj.092129 75. Johnstone J, Nerenberg K, Loeb M. Meta-analysis: Proton pump inhibitor use and the risk of community-acquired pneumonia. Aliment Pharmacol Ther 2010; 31: 1165–77. DOI: 10.1111/j.1365-2036.2010.04284.x 76. Zhou M, Zhang J, Liu J et al; CCC-ACS Investigators. Proton Pump Inhibitors and In-Hospital Gastrointestinal Bleeding in Patients With Acute Coronary Syndrome Receiving Dual Antiplatelet Therapy. Mayo Clin Proc 2022 Feb 12: S0025-6196(21)00919-8. DOI: 10.1016/j.mayocp.2021.11.037 77. Charpiat B, Bleyzac N, Tod M. Proton Pump Inhibitors are Risk Factors for Viral Infections: Even for COVID-19? Clin Drug Investig 2020; 40 (10): 897–9. DOI: 10.1007/s40261-020-00963-x 78. Almario CV, Chey WD, Spiegel BMR. Increased Risk of COVID-19 Among Users of Proton Pump Inhibitors. Am J Gastroenterol 2020; 115 (10): 1707–15. DOI: 10.14309/ajg.0000000000000798 79. Li GF, An XX, Yu Y et al. Do proton pump inhibitors influence SARS-CoV-2 related outcomes? A meta-analysis. Gut 2021; 70: 1806–8. DOI: 10.1136/gutjnl-2020-323366 80. Israelsen SB, Ernst MT, Lundh A et al. Proton Pump Inhibitor Use Is Not Strongly Associated With SARS-CoV-2 Related Outcomes: A Nationwide Study and Meta-analysis. Clin Gastroenterol Hepatol 2021; 19 (9): 1845–54.e6. DOI: 10.1016/j.cgh.2021.05.011 81. Toubasi AA, AbuAnzeh RB, Khraisat BR et al. Proton Pump Inhibitors: Current Use and the Risk of Coronavirus Infectious Disease 2019 Development and its Related Mortality. Meta-analysis. Arch Med Res 2021; 52 (6): 656–9. DOI: 10.1016/j.arcmed.2021.03.004 82. Yan C, Chen Y, Sun C et al. Does Proton Pump Inhibitor Use Lead to a Higher Risk of Coronavirus Disease 2019 Infection and Progression to Severe Disease? a Meta-analysis. Jpn J Infect Dis 2022; 75 (1): 10–15. DOI: 10.7883/yoken.JJID.2021.074 83. Kamal F, Khan MA, Sharma S et al. Lack of Consistent Associations Between Pharmacologic Gastric Acid Suppression and Adverse Outcomes in Patients With Coronavirus Disease 2019: Meta-Analysis of Observational Studies. Gastroenterology 2021; 160 (7): 2588-2590.e7. DOI: 10.1053/j.gastro.2021.02.028 84. Kim HB, Kim JH, Wolf BJ. Acid suppressant use in association with incidence and severe outcomes of COVID-19: a systematic review and meta-analysis. Eur J Clin Pharmacol 2022; 78 (3): 383–91. DOI: 10.1007/s00228-021-03255-1 85. Pranata R, Huang I, Lawrensia S et al. Proton pump inhibitor on susceptibility to COVID-19 and its severity: a systematic review and meta-analysis. Pharmacol Rep 2021; 73 (6): 1642–9. DOI: 10.1007/s43440-021-00263-x 86. Ramachandran P, Perisetti A, Gajendran M et al. Pre-hospitalization proton pump inhibitor use and clinical outcomes in COVID-19. Eur J Gastroenterol Hepatol 2022; 34 (2): 137–41. DOI: 10.1097/MEG. 0000000000002013 87. Симаненков В.И., Маев И.В., Ткачева О.Н. и др. Эпителий-протективная терапия при коморбидных заболеваниях. Практические рекомендации для врачей. Терапевтический архив. 2022; 94 (8): 6–22. DOI: 10.26442/00403660.2022.08.201523 [Simanenkov V.I., Maev I.V., Tkacheva O.N. et al. Epitelii-protektivnaia terapiia pri komorbidnykh zabolevaniiakh. Prakticheskie rekomendatsii dlia vrachei. Terapevticheskii arkhiv. 2022; 94 (8): 6–22. DOI: 10.26442/00403660.2022.08.201523 (in Russian).] 88. Трухан Д.И. Рациональная фармакотерапия в реальной клинической практике сквозь призму мультиморбидности и лекарственной безопасности. Клинический разбор в общей медицине. 2020; 2: 29–39. DOI: 10.47407/kr2020.1.2.00015 [Trukhan D.I. Ratsional'naia farmakoterapiia v real'noi klinicheskoi praktike skvoz' prizmu mul'timorbidnosti i lekarstvennoi bezopasnosti. Klinicheskii razbor v obshchei meditsine. 2020; 2: 29–39. DOI: 10.47407/kr2020.1.2.00015 (in Russian).] 89. Трухан Д.И., Иванова Д.С. Роль и место синдрома повышенной эпителиальной проницаемости в развитии сердечно-сосудистых и бронхолегочных заболеваний: теоретические и практические аспекты применения ребамипида. Фарматека. 2021; 28 (5): 115–26. DOI: 10.18565/pharmateca.2021.5.115-126 [Trukhan D.I., Ivanova D.S. Rol' i mesto sindroma povyshennoi epitelial'noi pronitsaemosti v razvitii serdechno-sosudistykh i bronkholegochnykh zabolevanii: teoreticheskie i prakticheskie aspekty primeneniia rebamipida. Farmateka. 2021; 28 (5): 115–26. DOI: 10.18565/pharmateca.2021.5.115-126 (in Russian).] 90. Трухан Д.И., Иванова Д.С. Лекарственная безопасность в реальной клинической практике: акцент на протекторную терапию. Фарматека. 2022; 3: 72–82. DOI: 10.18565/pharmateca.2022.3.72-82 [Trukhan D.I., Ivanova D.S. Lekarstvennaia bezopasnost' v real'noi klinicheskoi praktike: aktsent na protektornuiu terapiiu. Farmateka. 2022; 3: 72–82. DOI: 10.18565/pharmateca.2022.3.72-82 (in Russian).] 91. Naito Y, Yoshikawa T. Rebamipide: a gastrointestinal protective drug with pleiotropic activities. Expert Rev Gastroenterol Hepatol 2010; 4 (3): 261–70. DOI: 10.1586/ egh.10.25 92. Genta RM. Review article: the role of rebamipide in the management of inflammatory disease of the gastrointestinal tract. Aliment Pharmacol Ther 2003; 18 (Suppl. 1): 8–13. DOI: 10.1046/j.1365-2036.18.s1.5.x 93. Yang BR, Lee JY, Kim MG. The risk of pulmonary adverse drug reactions of rebamipide and other drugs for acid-related diseases: An analysis of the national pharmacovigilance database in South Korea. J Dig Dis 2022; 23 (2): 118–23. DOI: 10.1111/1751-2980.13075 94. Гриневич В.Б., Губонина И.В., Дощицин В.Л. и др. Особенности ведения коморбидных пациентов в период пандемии новой коронавирусной инфекции (COVID-19). Национальный Консенсус 2020. Кардиоваскулярная терапия и профилактика. 2020; 19 (4): 2630. DOI: 10.15829/1728-8800-2020-2630 [Grinevich V.B., Gubonina I.V., Doshchitsin V.L. et al. Management of patients with comorbidity during novel coronavirus (COVID-19) pandemic. National Consensus Statement 2020. Cardiovascular Therapy and Prevention. 2020; 19 (4): 2630. DOI: 10.15829/1728-8800-2020-2630 (in Russian).] 95. Wen X, Chen X, Zhou X. Rebamipide inhibited expression of TLR4 and TNF-alpha release in pulmonary epithelial cell line A549 induced by lipopolysaccharide. Zhong Nan Da Xue Xue Bao Yi Xue Ban 2009; 34 (5): 457–60. URL: https://pubmed.ncbi.nlm.nih.gov/19483297/ 96. Yasuda T, Chiba H, Satomi T et al. Preventive effect of rebamipide gargle on chemoradiotherpy-induced oral mucositis in patients with oral cancer: a pilot study. J Oral Maxillofac Res 2012; 2 (4): e3. DOI: 10.5037/jomr.2011.2403 97. Akagi S, Fujiwara T, Nishida M et al. The effectiveness of rebamipide mouthwash therapy for radiotherapy and chemoradiotherapyinduced oral mucositis in patients with head and neck cancer: a systematic review and meta-analysis. J Pharm Health Care Sci 2019; 5: 16. DOI: 10.1186/s40780-019-0146-2 98. Urita Y, Watanabe T, Maeda T et al. Rebamipide and mosapride enhance pilocarpine-induced salivation. N Am J Med Sci 2009; 1 (3): 121–4. URL: https://pubmed.ncbi.nlm.nih.gov/22666683/ 99. Гриневич В.Б., Кравчук Ю.А., Ткаченко Е.И. и др. Особенности ведения больных с гастроэнтерологической патологией в условиях пандемии COVID-19. Экспериментальная и клиническая гастроэнтерология. 2020; 176 (4): 3–18. DOI: 10.31146/1682-8658-ecg-176-4-3-18 [Grinevich V.B., Kravchuk Iu.A., Tkachenko E.I. et al. Features of management of patients with gastroenterological pathology in the conditions of the COVID-19 pandemic. Experimental and Clinical Gastroenterology. 2020; 176 (4): 3–18. DOI: 10.31146/1682-8658-ecg-176-4-3-18 (in Russian).] 100. Ткачева О.Н., Котовская Ю.В, Алексанян Л. А. и др. Согласованная позиция экспертов Российской ассоциации геронтологов и гериатров. Новая коронавирусная инфекция SARS-CoV-2 (COVID19) у пациентов пожилого и старческого возраста: особенности профилактики, диагностики и лечения. Кардиоваскулярная терапия и профилактика. 2020; 19 (3): 2601. DOI: 10.15829/1728-8800-2020-2601 [Tkacheva O.N., Kotovskaya Yu.V., Aleksanyan L.A et al. Novel coronavirus infection SARS-CoV-2 in elderly and senile patients: prevention, diagnosis and treatment. Expert Position Paper of the Russian Association of Gerontology and Geriatrics. Cardiovascular Therapy and Prevention. 2020; 19 (3): 2601. DOI: 10.15829/1728-8800-2020-2601 (in Russian).] 101. Особенности течения Long-COVID инфекции. Терапевтические и реабилитационные мероприятия. Методические рекомендации (утверждены на ХVI Национальном Конгрессе терапевтов 18.11.2021). URL: https://www.rnmot.ru/ru/library/clinical [Osobennosti techeniia Long-COVID infektsii. Terapevticheskie i reabilitatsionnye meropriiatiia. Metodicheskie rekomendatsii (utverzhdeny na KhVI Natsional'nom Kongresse terapevtov 18.11.2021). URL: https://www.rnmot.ru/ru/library/clinical (in Russian).] 102. Дробижев М.Ю. Сульпирид: механизм действия и возможности клинического использования. Психиатрия и психофармакотерапия. 2004; 4: 173–9. URL: https://www.elibrary.ru/ item.asp?id=26702734 [Drobizhev M.Iu. Sul'pirid: mekhanizm deistviia i vozmozhnosti klinicheskogo ispol'zovaniia. Psikhiatriia i psikhofarmakoterapiia. 2004; 4: 173–9. URL: https://www.elibrary.ru/item.asp? id=26702734 (in Russian).] 103. Данилов Д.С. Атипичный нейролептик сульпирид: спектр эффектов и возможности использования в клинической практике. Психиатрия и психофармакотерапия. 2011; 4: 19–27. URL: https://www.elibrary.ru/item.asp?id=16861398 [Danilov D.S. Atipichnyi neiroleptik sul'pirid: spektr effektov i vozmozhnosti ispol'zovaniia v klinicheskoi praktike. Psikhiatriia i psikhofarmakoterapiia. 2011; 4: 19–27. URL: https://www.elibrary.ru/item.asp?id=16861398 (in Russian).] 104. Данилов Д.С. Возможности использования сульпирида для лечения психических расстройств. Журнал неврологии и психиатрии им. C.C. Корсакова. 2012; 6: 91–8. URL: https://www.elibrary.ru/item.asp?id=17912115 [Danilov D.S. Vozmozhnosti ispol'zovaniia sul'pirida dlia lecheniia psikhicheskikh rasstroistv. Zhurnal nevrologii i psikhiatrii im. C.C. Korsakova. 2012; 6: 91–8. URL: https://www.elibrary.ru/ item.asp?id=17912115 (in Russian).] 105. Данилов Д.С. Полувековой опыт использования нейролептиков-бензамидов в психиатрии и соматической медицине (на примере сульпирида). Человек и Лекарство – Казахстан. 2015; 8 (54): 106–15. URL: https://www.elibrary.ru/item.asp? id=24069895 [Danilov D.S. Poluvekovoi opyt ispol'zovaniia neiroleptikov-benzamidov v psikhiatrii i somaticheskoi meditsine (na primere sul'pirida). Chelovek i Lekarstvo – Kazakhstan. 2015; 8 (54): 106–15. URL: https://www.elibrary.ru/item.asp?id=24069895 (in Russian).] 106. Трухан Д.И., Тарасова Л.В. Клиника, диагностика и лечение хронического дуоденита. Экспериментальная и клиническая гастроэнтерология. 2012; 11: 104–14. URL: https://www.elibrary.ru/item.asp?id=21589957 [Trukhan D.I., Tarasova L.V. Klinika, diagnostika i lechenie khronicheskogo duodenita. Eksperimental'naia i klinicheskaia gastroenterologiia. 2012; 11: 104–14. URL: https://www.elibrary.ru/ item.asp?id=21589957 (in Russian).] 107. Трухан Д.И. Тревожно-депрессивные расстройства у гастроэнтерологических пациентов в амбулаторно-поликлинической практике. Фармация и фармакология. 2015; S1: 116–7. URL: https://www.elibrary.ru/item.asp?id=25220383 [Trukhan D.I. Trevozhno-depressivnye rasstroistva u gastroenterologicheskikh patsientov v ambulatorno-poliklinicheskoi praktike. Farmatsiia i farmakologiia. 2015; S1: 116–7. URL: https://www.elibrary.ru/item.asp?id=25220383 (in Russian).]